---
canonical_name: 5-Amino-1MQ
alternate_names: 5-Amino-1-methylquinolinium, 5-AMQ, 5A1MQ, 5-Amino-1-methylquinoline
canonical_topic: 5-Amino-1MQ for Health & Longevity
short_topic_lc: 5_amino_1mq
creation_date: 2026-0715-0250
creator_ai_fullname: Opus 4.8
---

# 5-Amino-1MQ for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 07/15/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** 5-Amino-1-methylquinolinium, 5-AMQ, 5A1MQ, 5-Amino-1-methylquinoline


## Motivation

<!-- This motivation section was written after the rest of the document was completed, so that it accurately reflects the full scope of the review. -->

5-Amino-1MQ is a small molecule that blocks an enzyme which becomes overactive in fat tissue and in aging muscle. By quieting this enzyme, cells hold onto more of two ingredients they use to make energy and to keep their internal "housekeeping" running — one of which is a molecule called NAD⁺ that naturally declines with age. In laboratory animals, this shift pushed the body to burn stored fat rather than store it, without the animals eating less.

Interest grew after obese mice given the compound lost fat, handled blood sugar better, and developed less fatty liver, while separate work in old mice suggested it helped injured muscle recover. These findings, combined with the broader excitement around raising NAD⁺, moved 5-Amino-1MQ from the laboratory into the wider longevity and body-composition scene, where it is sold as a capsule despite having never been tested in a human study.

This review examines what is actually known about 5-Amino-1MQ: how it works, what the animal and cell evidence shows for fat loss, metabolic health, and muscle, what risks and unknowns remain, and how far the current science does — and does not — reach.


**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists high-level overviews and foundational sources that discuss 5-Amino-1MQ or its core mechanism — inhibition of NNMT (nicotinamide N-methyltransferase), an enzyme that consumes the NAD⁺ precursor nicotinamide — in substantial depth.

<!-- A real-time web search was performed across general search engines and the platforms of the priority experts (Rhonda Patrick/FoundMyFitness, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension). No priority expert has published content addressing 5-Amino-1MQ or NNMT inhibition by name in substantial depth; the items below are the most relevant high-level overviews and primary sources identified. -->

* [5-Amino 1MQ: Benefits, Dosage & Side Effects](https://jaycampbell.com/blog/5-amino-1mq-the-body-recomposition-peptide/) - Jay Campbell

  A widely read practitioner-facing overview from the body-optimization community that summarizes the mechanism, the animal evidence, and typical real-world dosing, while illustrating the promotional framing readers are likely to encounter.

* [Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice](https://pubmed.ncbi.nlm.nih.gov/29155147/) - Neelakantan et al., 2018

  The foundational primary paper that first characterized 5-Amino-1MQ, establishing its selectivity, cell permeability, and ability to reverse diet-induced obesity in mice — the origin of essentially every benefit claim made for the compound.

* [Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome](https://pubmed.ncbi.nlm.nih.gov/38919254/) - Sun et al., 2024

  A narrative review that explains why NNMT sits at the crossroads of the NAD⁺ and methylation systems and how inhibiting it may influence obesity, diabetes, and lipid handling, giving useful context for the metabolic rationale.

* [Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation](https://pubmed.ncbi.nlm.nih.gov/42067476/) - Puleo et al., 2026

  A recent review assessing how close NNMT inhibitors are to human use, candidly discussing the bioavailability and unknown-safety hurdles that separate promising animal data from validated therapeutics.

* [Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation](https://pubmed.ncbi.nlm.nih.gov/33453420/) - Roberti et al., 2021

  A mechanistic overview linking NNMT activity to both energy metabolism and gene regulation, helpful for understanding why a single enzyme influences fat, muscle, and aging biology at once.

Note: No content from the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension) could be found addressing this specific compound or its mechanism; the list is therefore drawn from the most relevant practitioner and academic sources available.


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool via its page-URL scheme. A dedicated article for 5-Amino-1MQ exists. -->

[5-Amino-1MQ](https://grokipedia.com/page/5-Amino-1MQ)

A dedicated encyclopedia entry summarizing the compound's chemistry, its NNMT-inhibition mechanism, pharmacokinetics, and reported metabolic and aged-muscle effects; it offers a broad orientation to the topic while carrying the optimistic framing typical of sources on this compound.


## Examine

<!-- examine.com was searched directly using the browser tool and via site-scoped web search. No dedicated page for 5-Amino-1MQ exists; Examine does not cover this research compound. -->

No Examine article exists for 5-Amino-1MQ. Examine.com focuses on dietary supplements and nutraceuticals with human evidence and does not currently cover 5-Amino-1MQ, an unapproved research compound with no human data.


## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool and confirmed via fetch; the site returns "no results" for 5-Amino-1MQ. -->

No ConsumerLab article exists for 5-Amino-1MQ. ConsumerLab tests commercially marketed vitamins and supplements and does not cover 5-Amino-1MQ, which is sold as an unregulated research compound rather than a mainstream supplement.


## Systematic Reviews

<!-- A real-time PubMed search was performed for "5-Amino-1MQ / 5-amino-1-methylquinolinium / NNMT inhibitor" combined with "systematic review OR meta-analysis". The only systematic reviews and meta-analyses retrieved concern NNMT expression as a prognostic biomarker in cancer, not 5-Amino-1MQ as an intervention. -->

No systematic reviews or meta-analyses for 5-Amino-1MQ were found on PubMed as of 07/15/2026.


## Mechanism of Action

5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective small-molecule inhibitor of **nicotinamide N-methyltransferase (NNMT)** — an enzyme (a protein that speeds up a chemical reaction) that attaches a methyl group (a small carbon-hydrogen tag) to nicotinamide, a building block of NAD⁺.

The primary mechanism follows from what NNMT normally does:

* **The reaction NNMT catalyzes:** NNMT takes nicotinamide (a form of vitamin B3 and a precursor to **NAD⁺**, nicotinamide adenine dinucleotide — a coenzyme cells use for energy production and DNA repair) and tags it with a methyl group donated by **SAM** (S-adenosylmethionine, the body's universal methyl donor). This produces **1-MNA** (1-methylnicotinamide, an excreted by-product) and **SAH** (S-adenosylhomocysteine).

* **What inhibition does:** By blocking NNMT, 5-Amino-1MQ prevents nicotinamide and SAM from being consumed in this reaction. In cultured fat cells this raised intracellular NAD⁺ and SAM, lowered 1-MNA, and suppressed the making of new fat (lipogenesis).

* **Downstream effects:** Higher NAD⁺ can support **sirtuin-1 (SIRT1**, an NAD⁺-dependent enzyme that regulates metabolism and stress resistance), while higher SAM can shift the methylation of genes toward a more metabolically active state (for example, favoring **PGC-1α**, a master regulator of mitochondrial and fat-burning genes). NNMT is over-expressed in fat tissue in obesity and in skeletal muscle with aging, which is why inhibiting it is proposed to be beneficial specifically in those tissues.

Competing mechanistic view: the NAD⁺-raising effect of NNMT inhibition is modest and tissue-specific, and some researchers argue that most of 5-Amino-1MQ's metabolic effect comes from preserving SAM and re-tuning gene methylation rather than from NAD⁺ elevation itself. Both explanations remain under investigation, and neither has been confirmed in humans.

Key pharmacological properties (from rodent data; no human pharmacology exists):

* **Selectivity:** High — it does not meaningfully inhibit structurally related methyltransferases or NAD⁺-salvage enzymes.

* **Half-life:** Approximately 3.8 hours after intravenous and 6.9 hours after oral dosing in rats.

* **Tissue distribution:** Distributes to metabolically active tissues including adipose (fat), skeletal muscle, and liver after subcutaneous dosing.

* **Metabolism and elimination:** As a small cationic molecule it is recovered in plasma and urine, indicating substantial renal (kidney) elimination; the specific metabolizing enzymes (e.g., **CYP**, cytochrome P450 liver enzymes) have not been characterized. Oral bioavailability in rats was about 38%.


## Historical Context & Evolution

5-Amino-1MQ was not repurposed from an older drug; it was purpose-built. In 2017–2018, researchers at the University of Texas set out to design small, selective, membrane-permeable inhibitors of NNMT as a new mechanism-of-action approach to obesity and type 2 diabetes. Among the methylquinolinium scaffolds they screened, the 5-amino substitution combined high potency with good cell permeability, making it the lead compound.

The reason it came to be considered for health optimization is that NNMT sits at the junction of two systems the longevity field already cared about: the NAD⁺ salvage pathway (energy and repair) and the SAM methyl-donor cycle (gene regulation). When early mouse studies showed fat loss without appetite suppression, and a 2019 study suggested benefits for aged muscle regeneration, the compound was rapidly adopted by the body-composition and longevity communities and sold online, well ahead of any human testing.

The scientific findings themselves are consistent in direction: across independent mouse studies, NNMT inhibition reduced adiposity, improved glucose handling, and reduced fatty liver. What has changed over time is sober recognition of the gap between animals and humans. Recent reviews emphasize that bioavailability, durable target engagement, and long-term safety in people remain unestablished, and that no clinical trial of 5-Amino-1MQ has been registered or reported. The evolution here is not a reversal but a maturing of caution: the mechanism remains promising, while the human evidence remains absent.


## Expected Benefits

A dedicated search of clinical databases, PubMed, and expert sources was performed to compile the benefit profile. A critical caveat frames every item below: **no human studies of 5-Amino-1MQ exist.** All efficacy evidence is from rodent or cell-culture work. A second caveat concerns who produced that evidence: the pivotal efficacy studies (Neelakantan et al., 2018; Babula et al., 2024) originate with the compound's developers at the University of Texas Medical Branch and the spin-out company Ridgeline Therapeutics, parties with a direct financial interest in its adoption — a conflict of interest to weigh when reading the animal results below. This ceilings the achievable evidence grade at "Low," and benefits that depend on human-specific claims (such as body recomposition in trained athletes) are "Speculative."

### Low 🟩

#### Reduction in Fat Mass and Body Weight

In diet-induced obese mice, 5-Amino-1MQ and closely related NNMT inhibitors reduced body weight, white fat mass, and fat-cell size, with a proposed mechanism of preserved SAM and NAD⁺ shifting fat cells away from making and storing fat and toward burning it. The evidence basis is several independent mouse studies plus supporting cell-culture data showing suppressed lipogenesis; notably, weight loss occurred without reduced food intake. The main limitation is that no human data confirm the effect or its size.

**Magnitude:** No human quantification exists; in obese mice, once-daily dosing over ~28 days dose-dependently limited body-weight and fat-mass gain and lowered total cholesterol versus vehicle-treated controls.

#### Improved Insulin Sensitivity and Glucose Control

NNMT inhibition improved oral glucose tolerance and insulin sensitivity and lowered elevated insulin in obese mice, consistent with reduced fat mass and improved liver metabolism. The proposed mechanism combines less fat accumulation with restored NAD⁺/SIRT1 signaling in metabolic tissues. The evidence is animal-only, and it is unknown whether lean or metabolically healthy humans — the likely users — would see any glucose benefit at all.

**Magnitude:** No human data; in obese mice, treatment improved oral glucose tolerance and insulin sensitivity and suppressed high fasting insulin relative to controls.

#### Reduced Liver Fat (Hepatic Steatosis)

In obese mice, 5-Amino-1MQ attenuated fatty-liver changes and immune-cell infiltration, reduced liver weight, size, and triglyceride content, and normalized the liver enzymes ALT (alanine transaminase) and AST (aspartate transaminase) — markers that rise with liver stress. The mechanism is thought to be reduced whole-body and hepatic fat storage. Evidence is confined to one well-characterized mouse study; human relevance is unproven.

**Magnitude:** No human data; in obese mice, liver triglycerides, liver weight/size, and ALT/AST were reduced toward normal versus controls.

#### Aged Skeletal Muscle Regeneration and Strength

In 24-month-old mice (roughly equivalent to advanced human age), NNMT inhibition after muscle injury increased muscle stem-cell (satellite-cell) activity, produced larger regenerating muscle fibers, and improved contractile strength, with a proposed mechanism of restored NAD⁺ balance reactivating aged, senescent stem cells. The evidence basis is a single controlled aged-mouse study supported by matching cell-culture results. Limitations are substantial: it is one study, in an injury model, and it does not test whether healthy humans gain muscle.

**Magnitude:** No human data; in injured aged mice, regenerating fiber cross-sectional area was roughly 2-fold larger and peak contractile torque about 70% higher than in untreated controls.

### Speculative 🟨

#### Cellular NAD⁺ Restoration and Longevity

The broadest claim made for 5-Amino-1MQ is that, by preventing NAD⁺ from being drained, it counters the age-related decline of this molecule and thereby supports "healthy aging." Mechanistically this is plausible — NNMT inhibition does raise NAD⁺ in some tissues — but there are no lifespan, healthspan, or aging-biomarker studies of 5-Amino-1MQ in any species, so the longevity framing rests on mechanism and extrapolation from the wider NAD⁺ field rather than on direct evidence.

#### Cognitive and Neuronal Energy Support

Marketing materials frequently claim improvements in focus, memory, and mental energy via enhanced neuronal NAD⁺. This is speculative: it is based on the general role of NAD⁺ in brain energy metabolism rather than on any study measuring cognition, mood, or brain endpoints with 5-Amino-1MQ. No controlled or anecdotal clinical data support a cognitive benefit.


## Benefit-Modifying Factors

Because human data are absent, the following are reasoned from the compound's biology and the populations most likely to respond.

* **Baseline adiposity and metabolic status:** Every documented benefit occurred in obese or metabolically stressed animals with elevated tissue NNMT. Lean, metabolically healthy users — common in the longevity audience — may have little baseline NNMT over-expression to inhibit and could therefore see smaller or negligible effects.

* **Age:** The muscle-regeneration signal appeared specifically in aged animals, where NNMT rises and stem-cell function declines. Older adults at the upper end of the target range may in principle be the most likely to benefit for muscle endpoints, whereas younger users may gain less.

* **Baseline NAD⁺ status:** Individuals with already-adequate NAD⁺ (e.g., from a nutrient-rich diet or NAD⁺ precursor use) may experience a smaller relative rise and blunted downstream effect.

* **Genetic variation in NNMT and methylation enzymes:** Because every documented benefit tracks with elevated tissue NNMT, common variants that raise baseline NNMT expression could enlarge the pool of over-active enzyme available to inhibit and, in principle, increase the benefit; conversely, variants in methylation-cycle enzymes such as **MTHFR** (methylenetetrahydrofolate reductase, an enzyme in folate/methyl metabolism) or **COMT** (catechol-O-methyltransferase, which uses the methyl donor SAM to break down certain neurotransmitters) could alter how the spared SAM is used. Both possibilities are mechanistically reasoned and unstudied for this compound.

* **Sex-based differences:** The pivotal rodent studies used predominantly male animals. Sex differences in fat distribution, NNMT expression, and methylation biology are plausible but have not been characterized for this compound.

* **Pre-existing conditions:** Fatty liver, insulin resistance, or early type 2 diabetes are the conditions the animal benefits map onto; people without these may have less to gain metabolically.


## Potential Risks & Side Effects

A dedicated search of drug-reference and toxicology sources was performed. The defining feature of the risk profile is absence of data: there are no published human safety studies, no formal toxicology package in the public domain, and no post-marketing surveillance. Animal studies reported no obvious adverse effects at the doses tested, but those were short, small, and not designed to detect subtle or long-term harm. Consequently, one risk is graded "Low" (unregulated product quality, where general evidence is strong) and the remainder are "Speculative."

### Low 🟥

#### Unregulated Product Quality and Contamination

5-Amino-1MQ is sold as a research compound and gray-market "peptide," outside pharmaceutical manufacturing standards. The risk is not from the molecule's known pharmacology but from what is actually in the capsule: independent testing of gray-market metabolic and "longevity" products has repeatedly found under- or over-dosing, wrong compounds, and contaminants. The consequence ranges from no effect to unexpected toxicity, and the user has no reliable way to verify identity or purity.

**Magnitude:** Not quantified in available studies.

### Speculative 🟨

#### Loss of 1-Methylnicotinamide (1-MNA) Signaling

NNMT's product, 1-MNA, is not merely waste — some research attributes anti-inflammatory and blood-vessel-protective actions to it. Chronically suppressing NNMT lowers 1-MNA, so it is theoretically possible that long-term use removes a beneficial signal. No study has measured whether this matters in living animals or humans.

#### Systemic Methylation Shifts from SAM Elevation

By sparing SAM, sustained NNMT inhibition could raise methyl-donor availability body-wide, potentially altering the methylation of DNA and other targets beyond the intended metabolic genes. Whether this produces unwanted epigenetic changes over months or years is unknown and untested.

#### Reduced Xenobiotic Clearance

NNMT also methylates certain foreign compounds and drugs as part of their processing. Inhibiting it could, in principle, slow the clearance of such substances and change their effects or toxicity. No interaction study has examined this for 5-Amino-1MQ.

#### Unknown Long-Term, Fertility, and Pregnancy Safety

There are no reproductive, developmental, carcinogenicity, or chronic-toxicity studies. Because the compound alters fundamental energy and methylation pathways active in every cell, the absence of long-term data is a meaningful unknown rather than a reassurance.


## Risk-Modifying Factors

* **Pre-existing liver or kidney impairment:** Rodent data indicate substantial renal elimination and hepatic tissue exposure; impaired kidney or liver function could alter clearance and exposure in unpredictable ways, and no dosing adjustment data exist.

* **Genetic variation in methylation enzymes:** Variants such as **MTHFR** (methylenetetrahydrofolate reductase, an enzyme in folate/methyl metabolism) or **COMT** (catechol-O-methyltransferase, which uses SAM to break down certain neurotransmitters) could interact with a SAM-sparing intervention, but this is theoretical and unstudied.

* **Sex differences:** Safety was assessed almost entirely in male animals; risks specific to females, including any hormonal or reproductive effects, are uncharacterized.

* **Baseline biomarkers:** Individuals with elevated homocysteine or abnormal liver enzymes at baseline have no data to guide whether NNMT inhibition helps, harms, or is neutral for those markers.

* **Age and polypharmacy:** Older users are more likely to take multiple medications, increasing the chance of the theoretical drug-clearance interactions noted above.


## Key Interactions & Contraindications

No formal human interaction studies exist; the following are mechanism-based and precautionary.

* **NAD⁺ precursors and vitamin B3 forms (supplements):** Nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), niacin, and nicotinamide act on the same NAD⁺ system. Severity: caution/additive. Consequence: overlapping or additive effects on NAD⁺ metabolism with unknown net result; effects have not been studied in combination.

* **Methyl-donor supplements (supplements):** SAMe, betaine (trimethylglycine), and high-dose folate/methylcobalamin also influence the methylation cycle. Severity: caution. Consequence: unpredictable additive shifts in methylation balance.

* **Prescription drugs cleared by methyltransferase pathways (prescription):** Agents whose metabolism depends on methyltransferase activity — for example thiopurines such as azathioprine and mercaptopurine (metabolized by thiopurine S-methyltransferase, TPMT, an enzyme that inactivates thiopurine drugs) or levodopa (a substrate of COMT) — could theoretically be affected if a SAM-sparing agent alters methyl-donor availability. Severity: caution/monitor. Consequence: altered drug levels; no specific pairs have been characterized.

* **Over-the-counter agents (OTC):** No specific OTC interactions are documented; standard caution applies given the absence of data.

* **Other longevity interventions:** Combining with other experimental metabolic compounds compounds the uncertainty; no combination has safety data.

* **Populations who should avoid it:** Pregnant or breastfeeding individuals (no reproductive data); people with active cancer or under cancer surveillance (NNMT and methylation biology intersect with tumor metabolism, and effects are unstudied in this setting); those with significant liver or kidney disease; and anyone unwilling to accept an intervention with zero human safety data. Because no severity thresholds (e.g., specific enzyme or function cut-offs) have been established for this compound, avoidance is framed categorically.


## Risk Mitigation Strategies

* **Third-party purity and identity testing:** Because the dominant near-term risk is product quality, obtain a batch-specific certificate of analysis (identity, purity, and contaminant screening from an independent laboratory) before use. This mitigates the contamination and mislabeling risk.

* **Conservative, single-agent dosing:** Avoid stacking with other NAD⁺ boosters or methyl-donor supplements initially, so that any effect or adverse event can be attributed and the additive-interaction risk is minimized.

* **Baseline and follow-up laboratory monitoring:** Check liver enzymes (ALT/AST), a metabolic panel, fasting glucose and insulin, a lipid panel, and homocysteine before starting and periodically thereafter, to detect any adverse shift early given the compound's effects on liver and methylation pathways.

* **Time-limited trials rather than open-ended use:** Given the absence of long-term safety data, limiting use to defined, short evaluation periods (e.g., 8–12 weeks) with reassessment reduces cumulative exposure to unknown long-term risks.

* **Medical supervision for at-risk individuals:** Anyone with liver, kidney, hormonal, or oncologic history should involve a clinician, mitigating the risk of an unmonitored interaction or contraindication.


## Therapeutic Protocol

There is no validated human protocol; no clinical trial has established a safe or effective dose. What follows describes how the compound is used in practice by community practitioners, explicitly flagged as unvalidated.

* **Commonly used form and dose:** 5-Amino-1MQ is most often sold and used as an **oral capsule**, typically labeled at 50 mg once daily, sometimes with a range of 50–150 mg reported anecdotally. These figures derive from vendor labeling and community practice, not from dose-finding studies.

* **Practitioner framing:** Body-composition practitioners (for example, sources such as Jay Campbell's writing) position it as a daily oral agent taken for a period of weeks; some clinics pair it with NAD⁺ therapy. No expert consensus or clinic-standardized protocol exists.

* **Competing approaches:** The main alternative "approach" to raising NAD⁺ is supplementation with NAD⁺ precursors (NR, NMN, niacin) or intravenous NAD⁺, which have at least some human data. Neither is presented here as the default; 5-Amino-1MQ is distinguished by acting on the enzyme that consumes NAD⁺ rather than by adding precursor.

* **Best time of day:** Not established. It is commonly taken in the morning; there is no chronobiology data to support any particular timing.

* **Half-life and dose splitting:** With a rodent half-life of roughly 4–7 hours, once-daily oral dosing is the norm in practice, though the short half-life is a theoretical argument for split dosing that has not been tested.

* **Genetic considerations:** Variants in methylation-related enzymes (MTHFR, COMT) could in theory influence response to a SAM-sparing agent, but no pharmacogenetic data exist to guide dosing.

* **Sex-based considerations:** Dosing has not been studied by sex; pivotal animal work used mostly males, so no sex-specific guidance can be given.

* **Age considerations:** Older adults are the group with the clearest theoretical rationale (higher tissue NNMT, muscle findings in aged animals), but there is no age-adjusted dosing evidence.

* **Baseline biomarkers and conditions:** Response is expected to be greatest in those with metabolic dysfunction; individuals who are already lean and metabolically healthy have no evidence of benefit and no tailored protocol.


## Discontinuation & Cycling

* **Lifelong vs. short-term:** There is no evidence to support indefinite use. Given the absent long-term safety data, use is best regarded as short-term and experimental rather than lifelong.

* **Withdrawal effects:** None are documented. As a metabolic enzyme inhibitor with a short half-life, no physical dependence or withdrawal syndrome is expected, but this has not been studied.

* **Tapering:** No tapering protocol is described or biologically indicated; the compound clears within roughly a day.

* **Cycling:** Whether cycling preserves any effect or reduces risk is unknown. Some practitioners cycle it (e.g., weeks on, weeks off) on general principles, but no data show this maintains efficacy or improves safety.


## Sourcing and Quality

* **Regulatory status of supply:** 5-Amino-1MQ is not an approved drug or a recognized dietary supplement. It is sold as a "research chemical" or gray-market "peptide," so no regulator verifies its identity, dose, or purity.

* **What to look for:** Prioritize vendors that provide a recent, batch-specific certificate of analysis from an independent laboratory documenting compound identity, purity (often marketed as ≥98–99%), and screening for heavy metals, solvents, and microbial contaminants. Absence of such testing is a red flag.

* **Formulation:** It is most commonly offered as oral capsules or tablets; some suppliers sell bulk powder. Capsule products with verified per-unit dosing are preferable to unmeasured powder.

* **Reputable sourcing:** No brand can be endorsed as reliably high quality on the basis of independent evidence. Where a clinician is involved, a compounding pharmacy that performs its own analytical verification is preferable to an online research-chemical vendor.


## Practical Considerations

* **Time to effect:** Not established in humans. In animal studies, metabolic changes accrued over about 4 weeks of daily dosing, so any real-world effect would likely require weeks, not days.

* **Common pitfalls:** Treating a compound with zero human data as if it were a proven supplement; stacking it immediately with multiple other agents so nothing can be attributed; trusting vendor purity claims without a certificate of analysis; and expecting fat-loss effects in a lean person for whom the animal rationale may not apply.

* **Regulatory status:** In major markets it is neither approved for human use nor sanctioned as a supplement; sale is typically labeled "for research use only," and human use is off-label and unmonitored.

* **Cost and accessibility:** It is readily available online at moderate cost, but accessibility should not be mistaken for validation; the low barrier to purchase outpaces the evidence base.


## Interaction with Foundational Habits

* **Sleep:** Indirect and unstudied. NAD⁺ metabolism intersects with circadian biology, so a theoretical influence on sleep timing exists, but no data show that 5-Amino-1MQ improves or disrupts sleep. No specific timing guidance can be given.

* **Nutrition:** Indirect and potentially additive. The compound's targets overlap with dietary vitamin B3 and methyl-donor nutrients (folate, B12, betaine), so nutritional status may modulate its effects. A nutrient-adequate diet is the sensible backdrop; there is no evidence for pairing it with any specific diet, though its animal benefits were demonstrated against a high-fat-diet background.

* **Exercise:** Potentially potentiating for muscle endpoints, by mechanism. The aged-muscle findings involved regeneration and strength, and exercise independently raises NAD⁺ and stimulates muscle repair, so the two could be complementary. No study has tested the combination, and there is no evidence it blunts or enhances training adaptations.

* **Stress management:** Direction unknown. Through NAD⁺/SIRT1 and methylation pathways there is a plausible indirect link to stress-response biology, but no data address cortisol, resilience, or stress outcomes with this compound.


## Monitoring Protocol & Defining Success

Because 5-Amino-1MQ acts on liver, metabolic, and methylation pathways, baseline testing before starting and periodic follow-up are prudent to detect benefit or harm. Baseline labs should be drawn before the first dose to establish each individual's starting point.

Ongoing monitoring is reasonable at roughly 8–12 weeks after starting, then every 3–6 months if use continues, with body composition tracked over the same intervals.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Fasting glucose | 75–90 mg/dL | Tracks the glucose-control benefit seen in animals | Fasting sample; conventional "normal" extends to 99 mg/dL, higher than the functional target |
| Fasting insulin | 2–5 µIU/mL | Detects insulin-sensitivity change | Pair with glucose to compute HOMA-IR (a calculated index of insulin resistance) |
| HbA1c | < 5.4% | Longer-term (≈3-month) glucose average | Not affected by short-term fasting; reflects prior weeks |
| ALT / AST | < 25 U/L (both) | Screens for the liver-fat benefit and for liver stress/harm | Conventional upper limits (~40 U/L) are higher than the functional target |
| Lipid panel (total, LDL, HDL, triglycerides) | Triglycerides < 80 mg/dL; HDL > 50 mg/dL | Animal data show cholesterol and triglyceride reductions | Fasting sample preferred for triglycerides |
| Homocysteine | 5–7 µmol/L | Watches the methylation (SAM/SAH) pathway the drug alters | Fasting; interpret alongside folate and B12 status |
| hs-CRP | < 1.0 mg/L | General marker of systemic inflammation | High-sensitivity assay; avoid testing during acute illness |

Qualitative markers to track alongside labs:

* Energy levels and daytime fatigue
* Body composition and waist measurement (visual and tape-measure changes)
* Exercise recovery and strength
* Cognitive clarity and focus (claimed but unproven)

Success would be defined as favorable movement in metabolic markers and body composition without any rise in liver enzymes or homocysteine and without new symptoms; a lack of measurable change, or any adverse shift, argues for discontinuation given the unproven benefit.


## Emerging Research

* **No registered human trials:** As of 07/15/2026, a search of ClinicalTrials.gov returned no registered clinical trials of 5-Amino-1MQ (or 5-amino-1-methylquinolinium) in any indication. The entire human evidence base remains at zero.

* **Preclinical metabolic program:** The most recent primary study advancing the compound is [Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction](https://pubmed.ncbi.nlm.nih.gov/39161060/) (Babula et al., 2024), from Ridgeline Therapeutics, which characterized 5A1MQ's pharmacokinetics and confirmed metabolic and liver benefits in obese mice — a step toward the safety and dosing data a human trial would require.

* **Clinical translation outlook:** A 2026 review, [Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation](https://pubmed.ncbi.nlm.nih.gov/42067476/) (Puleo et al., 2026), argues NNMT inhibitors are approaching human readiness while candidly identifying bioavailability, durable target engagement, and unknown safety as the remaining barriers — evidence that could strengthen the case if resolved.

* **Directions that could weaken the case:** The same literature notes that the NAD⁺ rise from NNMT inhibition is modest and tissue-specific, and that NNMT's product 1-MNA has its own protective roles; studies clarifying whether chronic inhibition removes beneficial signaling could weaken the rationale. Future work on off-target methylation effects (per [Roberti et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33453420/)) could similarly temper enthusiasm.

* **Cardiometabolic breadth:** Recent mechanistic work extending NNMT inhibition to [heart failure with preserved ejection fraction in a mouse model](https://pubmed.ncbi.nlm.nih.gov/40484359/) (Li et al., 2025) suggests the target may matter beyond obesity, a research area to watch that could either broaden or complicate the risk-benefit picture.


## Conclusion

5-Amino-1MQ is a purpose-built small molecule that blocks an enzyme, NNMT, which becomes overactive in fat tissue and aging muscle. By doing so, it helps cells hold onto more of the fuel-and-repair molecule NAD⁺ and the body's main methyl donor, nudging cells to burn fat rather than store it. In obese mice it reduced fat, improved blood-sugar handling, and lessened fatty liver, and in old mice it appeared to help injured muscle recover and regain strength.

The decisive point is how thin the human evidence is: there is none. Every benefit rests on animal and cell studies, much of it produced by the compound's own developers and the company commercializing it — a financial interest worth keeping in view. No clinical trial has ever been run, and the compound is sold outside any quality-control system, so what is in a given capsule is uncertain. The known risks are mostly unknowns — long-term effects, methylation shifts, reproductive safety, and product contamination have not been studied.

For a reader focused on health and longevity, the mechanism is genuinely interesting and the direction of the animal findings is consistent, but the gap between a promising target and a validated human intervention is wide and unbridged. The most honest reading is that 5-Amino-1MQ is an early-stage experimental compound whose real-world benefits and risks in people remain undefined, and whose current use runs well ahead of its evidence.


**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**